<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084911</url>
  </required_header>
  <id_info>
    <org_study_id>SP-PA-COV-301</org_study_id>
    <nct_id>NCT05084911</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase III Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Poong Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shin Poong Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase&#xD;
      III clinical trial to evaluate efficacy and safety of pyramax in mild to moderate COVID-19&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who require hospitalization or have died due to COVID-19 infection until post-dose D29.</measure>
    <time_frame>follow up to Day29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to sustained recovery (discharge) in hospitalized subjects (days)</measure>
    <time_frame>follow up to Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>29-day mortality after the first dose of the investigational product</measure>
    <time_frame>Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11-point WHO clinical progression scale for clinical symptoms at D3, D7, D14, D21, and D29 after administration of the IP and changes compared to baseline</measure>
    <time_frame>Day3, Day7, Day14, Day21, Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEWS at D3, D7, D14, D21, and D29 after administration of the IP and changes compared to baseline</measure>
    <time_frame>Day3, Day7, Day14, Day21, Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects requiring acute therapy for more than 24 hours in a hospital or acute treatment facility or who have died due to COVID-19 until D29 after administration</measure>
    <time_frame>follow up to Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who have newly diagnosed with pneumonia or aggravated pneumonia* according to baseline pneumonia criteria until D29 after administration of the IP</measure>
    <time_frame>follow up to Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in COVID-19 viral load at D2, D3, D5, D7, and D14</measure>
    <time_frame>Day2, Day3, Day5, Day7, Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects in the high-risk group** who require hospitalization or have died due to COVID-19 until post-dose D29</measure>
    <time_frame>follow up to Day29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1420</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pyramax tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyramax</intervention_name>
    <description>Pyronaridine-Artesunate(180/60mg) tablet for 3days.</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet for 3days.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males and females aged 19 years or older (or minimum age for adulthood or for&#xD;
             informed consent below 19 years for each country)&#xD;
&#xD;
          2. Patients with body weight ≥45 kg at screening&#xD;
&#xD;
          3. Patients with COVID-19 confirmed by RT-PCR before randomization&#xD;
&#xD;
          4. Patients confirmed with mild or moderate COVID-19, along with one or more symptoms in&#xD;
             association with COVID-19 within 5 days before randomization, who do not need&#xD;
             adjunctive oxygen therapy&#xD;
&#xD;
          5. Patients who are fully informed of this study, voluntarily decide to participate in&#xD;
             this study and provide written consent to comply with requirements for this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe or critical* COVID-19&#xD;
&#xD;
          2. Patients requiring hospitalization for therapeutic purposes for COVID-19 such as&#xD;
             oxygen therapy with a decrease of oxygen saturation (&lt;94%) at screening or higher&#xD;
             level of care, or who may be potentially transferred to another hospital other than&#xD;
             the clinical trial institution within 72 hours.&#xD;
&#xD;
          3. Patients who have received or who have planned to receive any anti-viral drugs to&#xD;
             treat COVID-19 infection or medications that may affect the course of treatment within&#xD;
             28 days before participating in this study or before a sufficient wash-out period&#xD;
             [more than five times the half-life of the drug, etc.] (the longer period between the&#xD;
             two is chosen).&#xD;
&#xD;
          4. Patients with one or more of the following infections in the past or present&#xD;
&#xD;
               1. Infection with need for systemic anti-infection treatment other than Corona virus&#xD;
                  (SARS-CoV-2)&#xD;
&#xD;
               2. Major infection with need for oral antibiotics or hospitalization within 30 days&#xD;
                  before administration of the investigational product by discretion of the&#xD;
                  investigator.&#xD;
&#xD;
          5. Patients with a known clinically significant anemia (Hemoglobin &lt;8.0 g/dL)&#xD;
&#xD;
          6. Patients with a known severe renal impairment (eGFR ≤ 30 mL/min/1.73 m2)&#xD;
&#xD;
          7. Patients with a known severe hepatic dysfunction&#xD;
&#xD;
          8. Patients with a known allergic reaction to the active ingredients (pyronaridine&#xD;
             tetraphosphate, artesunate) and other ingredients of the investigational product&#xD;
&#xD;
          9. Patients with a gastrointestinal disease or who underwent a surgery that can affect&#xD;
             the absorption, distribution, metabolism and excretion of the drug, or who have active&#xD;
             gastritis, gastrointestinal tract/rectal bleeding, gastric ulcer, and pancreatitis or&#xD;
             pancreatic function abnormalities (excluding general appendectomy or hernia repair&#xD;
             surgery)&#xD;
&#xD;
         10. Patients who cannot be orally administered with the Investigational Product&#xD;
&#xD;
         11. Pregnant, breast-feeding or females with positive pregnancy test at screening&#xD;
&#xD;
         12. Females and males who have child-bearing plan or who are unwilling to commit to the&#xD;
             use of the following methods of contraception* during study period and for 3 months&#xD;
             after the study period&#xD;
&#xD;
         13. Patients who have participated in another clinical study/device study and received the&#xD;
             investigational product/device within 28 days from signing the informed consent&#xD;
&#xD;
         14. Patients with Co-morbidity requiring surgery within 7 days before administration of&#xD;
             the investigational product, or life-threatening co-morbidity within 30 days before&#xD;
             administration of the investigational product&#xD;
&#xD;
         15. Patients with history of alcohol or drug abuse within 12 months before administration&#xD;
             of the investigational product&#xD;
&#xD;
         16. Patients whom the investigator considers inappropriate for the study due to chronic&#xD;
             underlying disease or other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji-Woong Ryu</last_name>
    <phone>spnct@shinpoong.co.kr</phone>
    <email>spnct@shinpoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungnam national University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eunpyeong St. Marys' Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahmyook Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pyramax</keyword>
  <keyword>Pyronaridine</keyword>
  <keyword>Artesunate</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Corona virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

